Strok:取栓治疗未增加白质病变患者症状性脑出血的风险

2021-10-21 “脑血管病及重症文献导读”公众号 “脑血管病及重症文献导读”公众号

许多大血管闭塞的患者同时患有不同程度的脑小血管疾病,除其他症状外,基线神经影像学上的白质病变(white matter lesions,WML)也反映了这一点。脑小血管疾病可能限制缺血性卒中或脑出血的

许多大血管闭塞的患者同时患有不同程度的脑小血管疾病,除其他症状外,基线神经影像学上的白质病变(white matter lesions,WML)也反映了这一点。脑小血管疾病可能限制缺血性卒中或脑出血的恢复。静脉溶栓治疗后,高负荷WML也与症状性颅内出血(sICH)有关。WML对大血管闭塞引起的缺血性卒中患者预后的重要性尚未得到充分研究。此外,只有少数研究探讨过 WML 对 EVT 预后的影响,并且结果不一致,这可能是由于选定的研究人群和不同的成像方法所致。平扫 CT(NCCT)很容易获得WML负荷信息,当它与其他预后因素的临床信息结合时,可能会有助于制订治疗决策,并可在EVT预后模型中实施。

2021年9月来自荷兰的Simone M. Uniken Venema等在 Stroke 上公布了他们的研究结果,他们利用MR CLEAN登记研究的数据,评估了常规血管内治疗的患者,WML负荷与影像学和临床结局之间的关系。

研究者分析了MR CLEAN登记研究的数据,这是一项前瞻性、多中心、观察性队列研究,研究对象为荷兰接受血管内治疗的患者。使用视觉分级量表对基线平扫 CT 的WML进行分级。主要结局是90天时改良Rankin量表的得分。

2014年3月至2017年11月期间纳入MR CLEAN登记研究的3180名患者中,对3046名患者进行了WML分级,并将其分类为无(n=1855;61%)、轻度(n=608;20%)或中度至重度(n=588;19%)。

838例(49%)无WML患者、192例(34%)轻度WML患者和130例(24%)中度至重度WML患者获得了良好的结局(改良Rankin量表评分,0-2)。随着WML分级的增高,功能结局越来越差,并且具有剂量-依赖性(轻度WML的调整后共同OR 1.34[95% CI,1.13–1.60],中度至重度WML的调整后共同OR 1.67[95% CI,1.39–2.01];Ptrend'<0.001)。WML分级增高与无效再通相关(Ptrend'<0.001),与早期神经功能恢复呈负相关(Ptrend'=0.041),但与成功再灌注或症状性颅内出血的概率无关。

最终作者认为,基线WML负荷的增加与急性缺血性卒中血管内治疗后较差的临床预后相关,但与成功再灌注或症状性颅内出血无关。

原始出处:

Simone M. Uniken Venema, et al. White Matter Lesions and Outcomes After Endovascular Treatment for Acute Ischemic Stroke: MR CLEAN Registry Results. Stroke. 2021;52:2849–2857.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765914, encodeId=21b61e659144e, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 19 11:01:10 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072850, encodeId=4eee10e285093, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:40:55 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479105, encodeId=107d14e9105e2, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526570, encodeId=aa8b15265e0ea, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062732, encodeId=adc41062e32ae, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:16:04 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765914, encodeId=21b61e659144e, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 19 11:01:10 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072850, encodeId=4eee10e285093, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:40:55 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479105, encodeId=107d14e9105e2, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526570, encodeId=aa8b15265e0ea, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062732, encodeId=adc41062e32ae, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:16:04 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-11-22 ms6000000414198546

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1765914, encodeId=21b61e659144e, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 19 11:01:10 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072850, encodeId=4eee10e285093, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:40:55 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479105, encodeId=107d14e9105e2, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526570, encodeId=aa8b15265e0ea, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062732, encodeId=adc41062e32ae, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:16:04 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765914, encodeId=21b61e659144e, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 19 11:01:10 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072850, encodeId=4eee10e285093, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:40:55 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479105, encodeId=107d14e9105e2, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526570, encodeId=aa8b15265e0ea, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062732, encodeId=adc41062e32ae, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:16:04 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765914, encodeId=21b61e659144e, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Jan 19 11:01:10 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072850, encodeId=4eee10e285093, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:40:55 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479105, encodeId=107d14e9105e2, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526570, encodeId=aa8b15265e0ea, content=<a href='/topic/show?id=5678e181141' target=_blank style='color:#2F92EE;'>#白质病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71811, encryptionId=5678e181141, topicName=白质病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fcf11728516, createdName=gongliu, createdTime=Sat Oct 23 05:01:10 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1062732, encodeId=adc41062e32ae, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 21 21:16:04 CST 2021, time=2021-10-21, status=1, ipAttribution=)]
    2021-10-21 1207866fm50(暂无昵称)

    谢谢分享

    0

相关资讯

Stroke:脑海绵状血管瘤造成脑出血后,病人有哪些特征?

患者的焦虑评分明显更差,但抑郁评分和社会满意度评分更好。

Stroke:谵妄对脑出血患者预后的影响

大多数ICH患者的急性谵妄会在出院后消退,这与持续性谵妄患者相比具有更好的结局。谵妄对结局的影响可以通过急性后康复进一步减轻。

Stroke:脑出血幸存者的脑小血管病与抑郁症

CSVD的严重程度与ICH前后的抑郁症诊断相关。与高血压动脉病相关的ICH患者相比,脑淀粉样血管病相关ICH幸存者更可能经历抑郁症,并且更有可能报告持续的抑郁症状,以及对抗抑郁药治疗发生抵抗。

Stroke:脑出血后的长期生存、死亡原因和5年死亡率趋势

由于心血管死亡风险增加了2倍,病例的存活率显著低于对照组。吸烟、血清胆固醇和使用抗凝药物与ICH患者死亡风险增加相关。ICH患者的五年死亡率随着时间的推移保持稳定。

磁共振上出现轻微脑出血,先考虑的病因有哪些?

观看完整课程回放:请点击下方图片:

JAMA Neurology:脑出血后卒中的抗血小板治疗,效果如何

本研究发现抗血小板治疗对复发性ICH或所有主要血管事件没有统计学上的显著影响